CoV2Research - May2020 - 18

serosurveillance program is necessary to provide
policy makers, researchers, and front-line medical
professionals with the data necessary to forecast and
respond to this fast-moving and dynamic threat."

is often low. Several monoclonal antibodies developed by Sino Biological have been used in clinical
testing of antigen detection and received promising
early results. Earlier this year, the company received
support from the Bill & Melinda Gates Foundation
on colloidal gold- and ELISA-based diagnosis of
COVID-19. The fund will be specifically used for the
optimization of key antigen and antibodies needed for rapid and high-throughput detection of
SARS-CoV-2.

Serological study of COVID-19
This latest development marks yet another important milestone in the company's efforts to develop
solutions for serological studies of this deadly virus.
Sino Biological is the first company to produce recombinant proteins of SARS-CoV-2. The company
launched the spike protein on January 22, only 12
days after the sequence was published.

"It's the company's long-standing mission to contribute to public health by providing high-quality
reagents for biomedical research professionals, especially those working on the diagnosis and treatment of infectious diseases," Sino Biological CEO Dr.
Jie Zhang stated. "We consider it a privilege to work
with physicians and researchers who are battling
against COVID-19 on the front line. Sino Biological
will continue to support COVID-19 research in whatever way we can."

Sino Biological has developed a large panel of reagents for COVID-19 research. The available products include hundreds of antigens, monoclonal antibodies, ELISA kits, inhibitor screening kits, antibody
titer kits, and expression vectors for SARS-CoV-2,
SARS-CoV, MERS-CoV, common coronavirus, and
their receptors. These reagents have supported hundreds of research groups around the globe for their
vaccine and antibody development works. The company is also offering pseudovirus-based infection assay services, allowing rapid screening of antibodies
and compounds for neutralization potential.

ProVirTM: Viral Antigen Bank
Sino Biological was engaged in the field of infectious
disease research long before the COVID-19 outbreak.
Powered by its recombinant platform proprietary
monoclonal antibody programs based on HEK293
and baculovirus-insect cells, the company has built a
huge collection of reagents over the years. In March,
Sino Biological officially announced the launch of the
world's largest viral antigen bank, ProVir™. This exclusive collection features over 800 antigens from 350
virus strains, including Zika, Ebola, Dengue, RSV, HIV,
and HPV. It's noteworthy that the ProVir™ collection
also carries 600+ HA, NA, and ME antigens from 250

The most important application of these reagents is
in serological diagnostics, both in forms of antigen
detection and antibody detection. Sino Biological's
recombinant S protein and N protein have both
been used to manufacture diagnostic kits detecting
serum antibodies against SARS-CoV-2. The antigen
detection is more difficult as compared to antibody
detection, as the viral titer in sera and nasal swabs

CoV2Research - May2020

Table of Contents for the Digital Edition of CoV2Research - May2020